Systemic Immune Activity Predicts Overall Survival in Treatment-Naïve Patients with Metastatic Pancreatic Cancer.
about
Targeting tumor-associated macrophages to combat pancreatic cancerReactivation of dormant anti-tumor immunity - a clinical perspective of therapeutic immune checkpoint modulation.The Exportin-1 Inhibitor Selinexor Exerts Superior Antitumor Activity when Combined with T-Cell Checkpoint Inhibitors.Lipocalin-2 Promotes Pancreatic Ductal Adenocarcinoma by Regulating Inflammation in the Tumor Microenvironment.IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.A circulating TH2 cytokines profile predicts survival in patients with resectable pancreatic adenocarcinoma.T-cell immunoglobulin mucin 3 blockade drives an antitumor immune response in head and neck cancer.CEACAM1 as a multi-purpose target for cancer immunotherapy.Ex Vivo PD-L1/PD-1 Pathway Blockade Reverses Dysfunction of Circulating CEA-Specific T Cells in Pancreatic Cancer Patients.Circulating monocyte chemoattractant protein-1 (MCP-1) is associated with cachexia in treatment-naïve pancreatic cancer patients.IL6 Receptor Blockade Enhances Chemotherapy Efficacy in Pancreatic Ductal Adenocarcinoma.BTN3A is a prognosis marker and a promising target for Vγ9Vδ2 T cells based-immunotherapy in pancreatic ductal adenocarcinoma (PDAC).Strategies for Increasing Pancreatic Tumor Immunogenicity.
P2860
Q28076103-221D8143-3B5A-4926-829E-7E7D45988ABCQ37593573-73AC5574-F2B9-412F-B410-DC5311DBE300Q38718460-611FE3A4-5074-4030-B79C-5D4F6968353FQ40312768-629AF839-50E3-42AF-8366-4B2F80CFDDE3Q40503359-56F93F13-7AAF-4225-BABF-58B16A3EB666Q41067756-34265BBC-0EA7-4DC1-B39D-7AA73D405A2DQ41127889-FEF91CE7-0DB2-4EEB-908B-E442304AA297Q41251368-2F32E933-E042-46EE-B1E8-3F32B4743272Q45941281-37F13C3B-9FEC-4D04-80AB-FBE9E1425510Q47217492-678A0B26-0B21-431D-BC56-8F422E5C87CFQ48764092-3836D489-BD87-4FAE-8242-371CCB557992Q50420977-A9BCC319-E7FD-42F5-AC7E-8C386A866A30Q52691832-87B5BD8D-D7A7-471A-AD64-3089107DF924
P2860
Systemic Immune Activity Predicts Overall Survival in Treatment-Naïve Patients with Metastatic Pancreatic Cancer.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Systemic Immune Activity Predi ...... Metastatic Pancreatic Cancer.
@en
type
label
Systemic Immune Activity Predi ...... Metastatic Pancreatic Cancer.
@en
prefLabel
Systemic Immune Activity Predi ...... Metastatic Pancreatic Cancer.
@en
P2093
P2860
P1476
Systemic Immune Activity Predi ...... Metastatic Pancreatic Cancer.
@en
P2093
Anne M Noonan
Christina Wu
Daniel Ahn
Gregory B Lesinski
Kristen Ciombor
Miguel Villalona-Calero
Sameh Mikhail
Sanaa Tahiri
Susan Geyer
Tanios Bekaii-Saab
P2860
P304
P356
10.1158/1078-0432.CCR-15-1732
P407
P577
2015-12-30T00:00:00Z